Cite
HARVARD Citation
Xiu, Y. et al. (2020). Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis. RSC advances. 10 (56), pp. 34197-34202. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Xiu, Y. et al. (2020). Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis. RSC advances. 10 (56), pp. 34197-34202. [Online].